3 курс / Фармакология / SNOTVORNYE_-NEYROLEPTIKI-I-PROTIVOEPILEPTICHESKIE-PREPARATY
.PDF
Эталоны ответов к задачам
Ответ 1
1.Бредовое расстройство.
2.Бредовое расстройство (F22.0)
3.Режим стационарный. При психомоторном возбуждении купирование хлорпромазин (до
200мг в сутки); трифтазин (до 30мг в сутки); в дальнейшем перевод на атипичные антипсихотики (рисполепт, оланзапин и т.д.); либо на нейролептики пролонгированного действия (например, «галоперидол-деканоат», «модитен-депо», «рисполепт-конста»).
Побочное действие: нейролептический синдром. Немедикаментозная терапия: социально -
психологическая реабилитация, индивидуальная психотерапия.
Ответ 2
1.Шизофрения параноидная, период наблюдения менее года.
2.Шизофрения параноидная, период наблюдения менее года. Галлюцинаторно -параноидный синдром. (F20.09)
3.Режим стационарный, диета - общий стол. Медикаментозное лечение: купирование острой симптоматики – хлорпромазин до 200 мг в стуки, галоперидол до 45 мг в сутки, в дальнейшем перевод на атипичные антипсихотики с индивидуальным.
Ответ 3
1.Шизофрения параноидная, непрерывное течение. Парафренный синдром.
2.Шизофрения параноидная, непрерывное течение. Парафренный синдром. (F20.00)
3.Режим стационарный, диета - общий стол. Медикаментозное лечение: купирование острой симптоматики – аминазин до 200 мг в стуки, галоперидол до 45 мг в сутки, в дальшнейшем перевод на атипичные антипсихотики с индивидуальным подбором дозы (рисполепт,
сероквель, оланзапин и т.д.); либо на нейролептики пролонгированного действия
(галоперидол-деканоат, модитен-депо до 100 мг в месяц, рисполепт – конста до 50 мг в месяц).
Побочные действия - нейролептический синдром (коррекция – циклодол до 8 мг в сутки),
метаболический синдром. Немедикаментозная терапия: социально-психологическая реабилитация, индивидуальная психотерапия.
Ответ 4
1.Органическое аффективное расстройство.
2.Органическое психотическое депрессивное расстройство в связи с травмой головного мозга.
Депрессивно-бредовой синдром (бред Котара) (F06.320)
3.Режим стационарный, диета - общий стол. Медикаментозное лечение: антидепрессанты селективные ингибиторы обратного захвата серотонина (СИОЗС) - флуоксетин 20 мг в сутки.
Трифтазин до 20 мг в сутки. Нейропротекторная и нейротрофическая терапия.
Немедикаментозная терапия: проведение рациональной психотерапии.
131
Ответ 5
1.Невралгия III ветви тройничного нерва слева.
2.Госпитализация желательна.
3.Консультация невролога, ЛОР врача, стоматолога.
4.МРТ головного мозга, придаточных пазух, МРТ ангиография.
5.При выявлении вазоневрального конфликта можно предложить хирургическое лечение;
прием антиконвульсантов (габапентин, прегабалин, карбамазепин).
132
Рекомендуемая литература Основная
1.Клиническфармакология: национальное руководство / под ред. Ю.Б. Белоу Лепахина, В.И. Петрова– М.: .ГЭОТАР-Медиа, 2014. – 976 с.– (Серия «Национальные руководства»).
2.Кукес, В. Г.,,Д.СычевА.Клиническая фармакология [Текст]: –уч5-ебникизд./, Виспр.Г. К доп–.М.: ГЭОТАР-Медиа, 2015–1024. с.
3.Кукес, В.Г., Стародубцев, А.К. Клиническая фармакология и фармакотерапия [Текс / В. Г. Кукес–3- изд. ., допераб.и –.перМ.: ГЭОТАР-Медиа, 2012–832. с.
4.Петров, В. И. Клиническая фармакология и фармакотерапия в реально мастер-класс [Текст]: учебник /–МВ..: ИГЭОТАР.Петров-Медиа,. 2014–880. с.
5. Харкевич, Д.А. Фармакология [Текст]:явузовучебник/ Д.А. дл–Харкевич10- изд.., испр., перер и доп–.М.: ГЭОТАРМедиа, 2010–752. с.
Дополнительная
6.Клинические рекомендации (стандарты ведения больных), выпуск 2,М.,20
7.Кукес В.Г. Клиническая фармакология. Учебник- M.-ГЕОТАРдля-МЕД,мед ВУЗов20064..
8.Михайлов И.Б. Клиническая фармакология,- 2000СПб,г. Фолиант.
133
Библиографический список
1.Adab N., Tudur Smith C., Vinten J. et al. Common antiepileptic drugs in pregnancy in women with epilepsy // Cochrane Database of Systematic Reviews. - 2004. - Issue 3. - Art. No.: CD004848. DOI: 10.1002/14651858.CD004848.
2.Adachi Y.U., Uchihashi Y., Watanabe K., Satoh T. Small dose midazolam or droperidol reduces the hypnotic dose of propofol at the induction of anaesthesia // European Journal of Anaesthesiology. - 2000 Feb.
3.Adams C.E., Eisenbruch M. Depot fluphenazine for schizophrenia // The Cochrane Library. - 2002. - Issue 3.
4.Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 2005; 28 (4): 197–204.
5.Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000; 85 (1): 129–35.
6.Ahuja N, Cole AJ. Hyperthermia syndromes in psychiatry. Adv Psychiatr Treat 2009; 15: 181–91.
7.Alldredge B.K., Gelb A.M., Isaacs S.M., Corry M.D., Allen F., Ulrich S., Gottwald M.D., O'Neil N., Neuhaus J.M., Segal M.R., Lowenstein D.H. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus // N Engl J Med. - 2001 Aug 30. - Vol. 345. - Issue 9. - P. 631-7. Accession Number PUBMED 11547716.
8.Als-Nielsen B., Gluud L.L., Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy // Cochrane Database of Systematic Reviews. - 2004. - Issue 2.
9.Al-Waneen R. Neuroleptic malignant syndrome associated with quetiapine. Can J Psychiatry 2000; 45 (8): 764–5.
10.Ananth J, Parameswaran S, Gunatilake S et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 464–70.
11.Anderson G.D., Gidal B.E., Messenheimer J.A., Gilliam F.G. Time course of lamotrigine de-induction: impact of step-wise
withdrawal of carbamazepine or phenytoin // Epilepsy Research. - 2002 May. - Vol. 49. - Issue 3. - P. 211-217.
12. Andrade C. Low-dose amisulpride and elevation in serum prolactin // J Clin Psychiatry. - 2013 Jun. - Vol. 74, no. 6. -
P.e558-60. - DOI:10.4088/JCP.13f08510. - PMID 23842026.
13.Andreassen MD, Pedersen S. Malignant neuroleptic syndrome. A review of epidemiology, risk factors, diagnosis, differential diagnosis and pathogenesis MNS. Ugeskr Laeger 2000; 162 (10): 1366–70.
14.Anti-epileptic drugs for preventing seizures following acute traumatic brain injury Schierhout G., Roberts I. This review should be cited as: Schierhout G., Roberts I. Anti-epileptic drugs for preventing seizures following acute traumatic brain injury // The Cochrane Library. - 2002. - Issue 3.
15.Appleton R., Martland T., Phillips B. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children // The Cochrane Database of Systematic Reviews. - 2002. - Issue 4. - Art. No.: CD001905. DOI: 10.1002/14651858.CD001905.
16.Appleton R., Sweeney A., Choonara I., Robson J., Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus // Developmental medicine and child neurology. - 1995 Aug. - Vol. 37. - Issue 8. - P. 682-8. Accession Number PUBMED 7672465.
17.Baldessarini R.J., Tarazi F.I. Медикаментозное лечение психозов и маний. В кн.: Клиническая фармакология по Гудману и Гилману. М.: «Практика». 2006, с. 382-411.
18.Barr J., Zomorodi K., Bertaccini E.J., Shafer S.L., Geller E. A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model // Anesthesiology. - 2001 Aug. - Vol. 95. - N 2. - P. 286-298.
19.Belgamwar R.B., Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses // Cochrane Database of Systematic Reviews. - 2005. - Issue 2.
20.Benjelloun G, Jehel L, Abgrall G et al. Acute catatonic syndrome after neuroleptic malignant syndrome. Encephale 2005; 31
(6 Pt 1): 705–9.
21. |
Benzer T. Neuroleptic Malignant Syndrome. Emergency medicine perspective. eMedicine 2007. |
–http://www.emedicine.com
22.Beydoun A., Sachdeo R.C., Kutluay E. et al. Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy // Epilepsia. - 2003. - Sep. - Vol. 44. - Issue 9. - P. 1160-1165. - Accession Number PUBMED 12919387.
23.Biton V., Edwards K.R., Montouris G.D. et al. Topiramate titration and tolerability // Ann. Pharmacother. - 2001 Feb. - Vol. 35 (2). - P. 173-179.Click here to read. Accession Number PUBMED 11215835.
24.BNF for children 2005. Paediatric Formulary Committee 2004-2005 / Ed. Dinesh K. Mehta. - BMJ Publishing Group Ltd, Royal Pharmaceutical Society of Great Britain, RCPCH Publication Ltd, 2005. - 866 p.
25.Bottoni TN. Neuroleptic Malignant Syndrome: A Brief Review Hospital Physician March 2002; 58–63: www.turner-
white.com
26.Bridle C., Palmer S., Bagnall A.-M., Darba J., Duffy S., Sculpher M. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder // Health Technology Assessment. - 2004. - Vol.8. - № 19. - The National Coordinating Centre for Health Technology Assessment (NCCHTA) on behalf of CRD, York.
27.Brooks J.L., Baker G.A., Goodfellow L., Bodde N., Aldenkamp A. Behavioural treatments for non-epileptic attack disorder // The Cochrane Database of Systematic Reviews. - 2007. - Issue 1. - Art. No.: CD006370. DOI: 10.1002/14651858.CD006370.
28.Bruggeman R., van der Linden C., Buitelaar J.K. et al. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study // Journal of Clinical Psychiatry. - 2001 Jan. - Vol. 62. - N 1. - P. 50-56.
29.Brunton L., Lazo J., Parker K. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. - 11th ed. - McGraw-Hill Professional, 2005. - 1984 p.
30.Buckley PF, Adityanjee, Sajatovic M. Neuroleptic malignant syndrome. In: Bashir Y et al., editors. Textbook of Neuromuscular Disorders. Philadelphia: Butterworth-Heinemann, 2001.
31.Buitelaar J.K., van der Gaag R.J., Cohen-Kettenis P. et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities // Journal of Clinical Psychiatry. - 2001 Apr. - Vol. 62. - N 4. - P. 239248.
32.C. Ntais, E. Pakos, P. Kyzas, J.P.A. Ioannidis. Benzodiazepines for alcohol withdrawal // The Cochrane Database of Systematic Reviews. - 2005. - Issue 3. - Art. No.: CD005063. DOI: 10.1002/14651858.CD005063.pub2.
33.Carlisle J.B., Stevenson C.A. Drugs for preventing postoperative nausea and vomiting // Cochrane Database of Systematic Reviews. - 2006. - Issue 3. - Art. No.: CD004125. DOI: 10.1002/14651858.CD004125.
34.Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63 (suppl. 4): 12–9.
35.Caroff SN, Mann SC, Keck PE Jr, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 2000; 20 (2): 257–9.
134
36.Caroff SN. Neuroleptic malignant syndrome. In: Mann SC, Caroff SN, Lazarus A, editors. Neuroleptic Malignant Syndrome and Related Conditions, 2nd ed. Washington DC: American Psychiatric Publishing 2003; 1–44.
37.Castillo S., Schmidt D.B., White S. Oxcarbazepine add-on for drug-resistant partial epilepsy // The Cochrane Database of Systematic Reviews. - 2000. - Issue 3. - Art. No.: CD002028. DOI: 10.1002/14651858.CD002028
38.Ceskova E. Risperidone in bipolar disorders // Ceska a Slovenska Psychiatrie. - 2001. - Vol. 97. - N 8. - P. 418-421.
39.Chaisewikul R., Privitera M.D., Hutton J.L., Marson A.G. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy // The Cochrane Database of Systematic Reviews. - 2001. - Issue 1. Art. No.: CD001901. DOI: 10.1002/14651858.CD001901.
40.Chakrabarti S, Sharma D, Singh G. Neurological Sequelae of Neuroleptic Malignant Syndrome. Hong Kong J Psychiatry
2001; 11 (3): 18–20.
41.Chandran M, El-Shazly M. Catatonia, neuroleptics and brain damage – a case report. J Psychopharmacol 2009; 23 (2): 223–
6.
42.Chen Y, Guo JJ, Steinbuch M et al. Risk of neuroleptic malignant syndrome in patients with bipolar disorder: a retrospective, population-based case-control study. Int J Psychiatry Med 2009; 39 (4): 39–50.
43.Chessick C.A., Allen M.H., Thase M.E. ABC Batista Miralha da Cunha, FFK Kapczinski, MSML de Lima, JJSS dos Santos Souza. Azapirones for generalized anxiety disorder // The Cochrane Database of Systematic Reviews. - 2006. - Issue 3. - Art. No.: CD006115. DOI: 10.1002/14651858.CD006115.
44.Chessick C.A., Allen M.H., Thase M.E., Batista Miralha da Cunha A.B.C., Kapczinski F.F.K., de Lima M.S.M.L., dos Santos Souza J.J.S.S. Azapirones for generalized anxiety disorder // The Cochrane Database of Systematic Reviews. - 2006. - Issue 3. - Art. No.: CD006115. DOI: 10.1002/14651858.CD006115.
45.Chronicle E., Mulleners W. Anticonvulsant drugs for migraine prophylaxis // Cochrane Database of Systematic Reviews. - 2004. - Issue 3. Art. No.: CD003226. DOI: 10.1002/14651858.CD003226.
46.Chronicle E., Mulleners W. Anticonvulsant drugs for migraine prophylaxis // The Cochrane Database of Systematic Reviews.
-2004. - Issue 3. - Art. No.: CD003226. DOI: 10.1002/14651858.CD003226.
47.Chronicle E., Mulleners W. Anticonvulsant drugs for migraine prophyla-xis // The Cochrane Database of Systematic Reviews. - 2004. - Issue 3. Art. No.: CD003226. DOI: 10.1002/14651858.CD003226.
48.Cipriani A., Rendell J.M., Geddes J.R. Haloperidol alone or in combination for acute mania // Cochrane Database of Systematic Reviews. - 2006. - Issue 3. - Art. No.: CD004362. DOI: 10.1002/14651858.CD004362.
49.Contin M., Riva R., Albani F. et al. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs // Therapeutic Drug Monitoring. - 2002 Jun. - Vol. 24. - Issue 3. - P. 332-337. Accession Number PUBMED 12021622.
50.Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008; 69 (7): 1157–65.
51.Cudkowicz M.E., Shefner J.M., Schoenfeld D.A. et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis // Neurology. - 2003 Aug. - Vol. 61. - Issue 4. - P. 456-464. Accession Number PUBMED 12939417.
52.Cure S.J., Rathbone J., Mandriota-Carpenter S.L. Droperidol for acute psychosis // Cochrane Database of Systematic Reviews. - 2004. - Issue 1.
53.Dahlin M., Knutsson E., Amark P., Nergardh A. Reduction of epileptiform activity in response to low-dose clonazepam in children with epilepsy: a randomized double-blind study // Epilepsia. - 2000 Mar. - Vol. 41. - Issue 3. - P. 308-315. Accession Number PUBMED 10714402.
54.David A., Adams C.E., Eisenbruch M. et al. Depot fluphenazine decanoate and enanthate for schizophrenia // Cochrane Database of Systematic Reviews. - 2004. - Issue 2. Art. No.: CD000307. DOI: 10.1002/14651858.CD000307.
55.David A., Quraishi S., Rathbone J. Depot perphenazine decanoate and enanthate for schizophrenia // Cochrane Database of Systematic Reviews. - 2005. - Issue 3. Art. No.: CD001717. DOI: 10.1002/14651858.CD001717.
56.Denis C., Fatséas M., Lavie E., Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings // Cochrane Database of Systematic Reviews. - 2006. - Issue 3. Art. No.: CD005194. DOI: 10.1002/14651858.CD005194.
57.Desai A. Use of psychopharmacologic agents in the elderly. Clin Geriatr Med 2003; 19 (4): 697–719.
58.Dinesh K. Mehta. BNF for children 2005 // Paediatric Formulary Committee. - 2004-2005. - 866 p.
59.Dinesh K. Mehta. BNF for children 2005. Paediatric Formulary Committee 2004-2005. - 866 p.
60.Draper R. Neuroleptic malignant syndrome. 2009: www.patient.co.uk/showdoc
61.Duggan L., Fenton M., Rathbone J. et al. Olanzapine for schizophrenia // The Cochrane Library. - 2005. Issue 2.
62.Duley L., Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia // The Cochrane Database of Systematic Reviews. - 2003. - Issue 4. - Art. No.: CD000127. DOI: 10.1002/14651858.CD000127.
63.E. Hancock, J. Osborne. Treatment of infantile spasms // The Cochrane Database of Systematic Reviews. - 2002. - Issue 2. - Art. No.: CD001770. DOI: 10.1002/14651858.CD001770.
64.E. Ng, A. Taddio, A. Ohlsson. Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit // The Cochrane Database of Systematic Reviews. - 2003. - Issue 1. - Art. No.: CD002052. DOI: 10.1002/14651858.CD002052.
65.Emilien G., Maloteaux J.M., Seghers A., Charles G. Lithium compared to valproic acid and carbamazepine in the treatment of mania: a statistical meta-analysis // European Neuropsychopharmacology. - 1996. - Vol. 6. - Issue 3. - P. 245-252.
66.Fay M.A., Sheth R.D., Gidal B.E. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas // Clinical therapeutics. - 2005 May. - Vol. 27. - Issue 5. - P. 594-598. Accession Number PUBMED 15978308.
67.Fearnley D., Nathan T. Antiepileptics for aggression and impulsiveness // The Cochrane Database of Systematic Reviews. - 2002. - Issue 1. - Art. No.: CD003499. DOI: 10.1002/14651858.CD003499.
68.Fischer T.L., Pieper J.A., Graff D.W. et al. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers // Clinical Pharmacology and Therapeutics. - 2002 Sep. - Vol. 72. - Issue 3. - P. 238-246. Accession Number PUBMED 12235444.
69.Flesch G., Tudor D., Denouel J. et al. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a filmcoated tablet in healthy subjects // International journal of clinical pharmacology and therapeutics. - 2003. - Jul. - Vol. 41. - Issue 7. - P. 299-308. - Accession Number PUBMED 12875346.
70.Friedberg JM. Neuroleptic malignant syndrome. 2006: URL: http://www.idiom.com/~drjohn/biblio.html
71.Fu L., Qiu X.-J., Dai Z.-S. et al. Relative bioavailability of oxcarbazepine tablets in healthy volunteers // Journal of China Pharmaceutical University. - 2004. - Vol. 35. - Issue 3. - P. 244-247.
72.Furukawa T.A., Streiner D.L., Young L.T., Kinoshita Y. Antidepressants plus benzodiazepines for major depression // The Cochrane Database of Systematic Reviews. - 2001. - Issue 3. - Art. No.: CD001026. DOI: 10.1002/14651858.CD001026.
73.Gamble C.L., Williamson P.R., Marson A.G. Lamotrigine versus carbamazepine monotherapy for epilepsy // The Cochrane Database of Systematic Reviews. - 2006. - Issue 1. Art. No.: CD001031. DOI: 10.1002/14651858.CD001031.
74.Gidal B.E., Baltes E., Otoul C., Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials // Epilepsy research. - 2005 Mar-Apr. - Vol. 64. - Issue 1-2. - P. 1-11. Accession Number PUBMED 15823510.
135
75.Gilbody S.M., Bagnall A.M., Duggan L., Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia // The Cochrane Library. - 2002. - Issue 3.
76.Gillies D., Beck A., McCloud A., Rathbone J. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis // The Cochrane Database of Systematic Reviews. - 2005. - Issue 4. - Art. No.: CD003079. DOI: 10.1002/14651858.CD003079.pub2.
77.Gillman PK. Neuroleptic malignant syndrome: Mechanisms, interactions, and causality. Mov Disord 2010; 25 (12): 1780–
90.
78.Glazener C.M.A., Evans J.H.C., Peto R.E. Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics)
//The Cochrane Database of Systematic Reviews. - 2003. - Issue 4. - Art. No.: CD002238. DOI: 10.1002/14651858.CD002238.
79.Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson’s disease. Mov Disord 2001; 16 (5): 960–2.
80.Grace R.F., Lesteour T., Sala T., Stewart J. A randomised comparison of low-dose ketamine and lignocaine infiltration with ketamine-diazepam anaesthesia for post partum tubal ligation in Vanuatu // Anaesthesia and intensive care. - 2001. - Vol. 29. - Issue 1. - P. 30-33.
81.Grossman F., Okamoto A., Bowden C.L. Risperidone plus mood stabilizer versus placebo plus mood stabilizer in patients with bipolar disorder: a combined efficacy analysis // 39th Annual Meeting of the American College of Neuropsychopharmacology. - 2000 Dec.
82.Gupta S, Nihalani ND. Neuroleptic Malignant Syndrome: A Primary Care Perspective. J Clin Psychiatry 2004; 6 (5): 191–4.
83.Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol 2002;
25 (4): 183–93.
84.H.H.G. Handoll, R. Madhok, C. Dodds. Anaesthesia for treating distal radial fracture in adults // The Cochrane Database of Systematic Reviews. - 2002. - Issue 3. - Art. No.: CD003320. DOI: 10.1002/14651858.CD003320.
85.Hadad E, Weinbroum AA, Ben-Abraham R. Drug-induced hyperthermia and muscle rigidity: a practical approach. Eur J Emerg Med 2003; 10 (2): 149–54.
86.Hajak G., Muller W.E., Wittchen H.U., Pittrow D., Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data // Addiction. - 2003. - Vol. 98 (10). - P. 1371-1378.
87.Hall RC, Appledy B, Hall RC. Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly. South Med J 2005; 98 (1): 114–7.
88.Hall RCW, Hall RCW, Chapman M. Neuroleptic Malignant Syndrome in the Elderly. Diagnostic Criteria, Incidence, Risk Factors, Pathophysiology, and Treatment. Clin Geriatrics 2006; 14 (5): 39–46.
89.Hammergren DJ. Neuroleptic malignant syndrome: an online resource for healthcare providers. The university of Arizona
2006; 61.
90.Hancock E., Cross H. Treatment of Lennox-Gastaut syndrome // Cochrane Database of Systematic Reviews. - 2003. - Issue 3. Art. No.: CD003277. DOI: 10.1002/14651858.CD003277.
91.Hancock E., Osborne J. Treatment of infantile spasms // Cochrane Database of Systematic Reviews. - 2002. - Issue 2. Art. No.: CD001770. DOI: 10.1002/14651858.CD001770.
92.Hancock E., Osborne J.P., Milner P. Treatment of infantile spasms (Cochrane Review) // The Cochrane Library. - 2002. - Issue 3. - Oxford: Update Software.
93.Harada T, Mitsuoka K, Kumagai R et al. Clinical fealures of malignant syndrome in Parkinson’s disease and related neurological disorders. Parkinsonism Relat Disord 2003; 9(suppl. 1): S15–23.
94.Harousseau J.L., Zittoun R., Bonneterre J., Hedouin M., Ouvry J. Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination // Bull Cancer. - 2000 Jun. - Vol. 87. - Issue 6. - P. 491-7. Accession Number PUBMED 10903790.
95.Hartung B., Wada M., Laux G. et al. Perphenazine for schizophrenia // Cochrane Database of Systematic Reviews. - 2005. - Issue 1. Art. No.: CD003443. DOI: 10.1002/14651858.CD003443.
96.Hesslinger B., Walden J., Normann C. Acute and long-term treatment of catatonia with risperidone. Pharmacopsychiatry.
2001; 34 (1): 25-26.
97.Hirst A., Sloan R. Benzodiazepines and related drugs for insomnia in palliative care // Cochrane Database of Systematic Reviews. - 2001. - Issue 4. Art. No.: CD003346. DOI: 10.1002/14651858.CD003346.
98.Holbrook A.M., Crowther R., Lotter A., Cheng C., King D. Meta-analysis of benzodiazepine use in the treatment of insomnia
//Canadian Medical Association Journal. - 2000. - Vol. 162 (2). - P. 225-233.
99.Hosalli P., Davis J.M. Depot risperidone for schizophrenia // Cochrane Database of Systematic Reviews. - 2003. - Issue 4.
100.Huf G., Alexander J., Allen M.H. Haloperidol plus promethazine for psychosis induced aggression // Cochrane Database of Systematic Reviews. - 2004. - Issue 4. - Art. No.: CD005146. DOI: 10.1002/14651858.CD005146.
101.Huf G., Alexander J., Allen M.H. Haloperidol plus promethazine for psychosis induced aggression // The Cochrane Database of Systematic Reviews. - 2004. - Issue 4. - Art. No.: CD005146. DOI: 10.1002/14651858.CD005146.
102.Ipser J.C., Carey P., Dhansay Y. et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders // Cochrane Database of Systematic Reviews. - 2006. - Issue 4. Art. No.: CD005473. DOI: 10.1002/14651858.CD005473.
103.Izurieta R., Rabatin J.T. Sedation during mechanical ventilation: a systematic review // Critical Care Medicine. - 2002. -
30(12):2644-2648.
104.Jackson K.C., Lipman A.G. Drug therapy for delirium in terminally ill patients // The Cochrane Database of Systematic Reviews. - 2004. - Issue 2. - Art. No.: CD004770. DOI: 10.1002/14651858.CD004770.
105.Jasovic Gasic M., Nikolic Balkoski G., Kuzmanovic V., Tasic A. The effects of benzodiazepines Hypnotics on performance and recent memory during the therapy of insomnia in schizophrenic patients Conference Abstract // 9th European College of Neuropsychopharmacology Congress. Amsterdam, The Netherlands. - 21st-25th September. - 1996.
106.Jayaram M.B., Hosalli P., Stroup S. Risperidone versus olanzapine for schizophrenia // Cochrane Database of Systematic Reviews. - 2006. - Issue 2.
107.Jesner O.S., Aref-Adib M., Coren E. Risperidone for autism spectrum disorder // Cochrane Database of Systematic Reviews.
- 2007. - Issue 1.
108.Jette N.J., Marson A.G., Hutton J.L. Topiramate add-on for drug-resistant partial epilepsy // Cochrane Database of Systematic Reviews. - 2002. - Issue 3. Art. No.: CD001417. DOI: 10.1002/14651858.CD001417.
109.Johnson SB, Alvarez WA, Freinhar JP. Rhabdomyolysis in retrospect: are psychiatric patients predisposed to this little known syndrome? Int J Psychiatry Med 1987; 17: 163–71.
110.Joy C.B., Adams C.E., Lawrie S.M. Haloperidol versus placebo for schizophrenia // Cochrane Database of Systematic Reviews. - 2006. - Issue 4. - Art. No.: CD003082. DOI: 10.1002/14651858.CD003082.
111.K.J. Walker, A.F. Smith, A.J. Pittaway. Premedication for anxiety in adult day surgery // The Cochrane Database of Systematic Reviews. - 2003. - Issue 1. - Art. No.: CD002192. DOI: 10.1002/14651858.CD002192.
112.Keck PE Jr, Arnold LM. The serotonin syndrome. Psychiatr Ann 2000; 30: 333–43.
113.Khaidi S, Kornreich C, Choubani Z, Gourevitch R. Neuroleptic malignant syndrome and atypical antipsychotics: a brief review. Encephale 2008; 34 (6): 618–24.
114.Khan HM, Syed NA, Sheerani M et al. Neuroleptic malignant syndrome: need for early diagnosis and therapy. J Ayub Med Coll Abbottabad 2006; 18 (1): 17–21.
136
115.Kirchner V., Kelly C.A., Harvey R.J. Thioridazine for dementia // Cochrane Database of Systematic Reviews. - 2001. - Issue
4.Art. No.: CD000464. DOI: 10.1002/14651858.CD000464.
116.Kirchner V., Kelly C.A., Harvey R.J. Thioridazine for dementia // The Cochrane Database of Systematic Reviews. - 2001. - Issue 4. - Art. No.: CD000464. DOI: 10.1002/14651858.CD000464.
117.Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (Dec 8, 2010). «Second-generation antipsychotics for major
depressive |
disorder |
and |
dysthymia». The |
Cochrane |
database |
of |
systematic |
reviews (12): |
CD008121. DOI:10.1002/14651858.CD008121.pub2. PMID 21154393. |
|
|
|
|
||||
118.Kumar R., Narang A., Kumar P., Garewal G. Phenobarbitone prophylaxis for neonatal jaundice in babies with birth weight 1000-1499 grams // Indian Pediatrics. - 2002 Oct. - Vol. 39. - Issue 10. - P. 945-951. Accession Number PUBMED 12428041.
119.Lai EC, Hsieh CY, Kao Yang YH, Lin SJ. Detecting potential adverse reactions of sulpiride in schizophrenic patients by
prescription |
sequence |
symmetry |
analysis // |
PLoS |
One. - |
2014 |
Feb. - |
Vol. 27;9, |
no. 2. - |
P.e89795. - DOI:10.1371/journal.pone.0089795. - PMID 24587038.
120.Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J. Practice Guideline for the Treatment of Patients With Schizophrenia. - 2nd ed. - American Psychiatric Association, 2004. Перевод фрагмента: Применение нейролептиков при шизофрении // Стандарты мировой медицины. - 2005. - № 2/3. - С. 83-112.
121.Lemoine P., Touchon J., Billardon M. Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo // L'Encéphale. - Vol. 23. - Issue 4. - P. 290-299.
122.Leppik I.E., Derivan A.T., Homan R.W., Walker J., Ramsay R.E., Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus // J.A.M.A.: The journal of the American Medical Association. - 1983 Mar 18. - Vol. 249. - Issue 11. - P. 1452-1454. - Accession Number PUBMED 6131148.
123.Leucht S., Hartung B. Perphenazine for schizophrenia // The Cochrane Library. - Issue 3. - 2002.
124.Leucht S., McGrath J., White P., Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses // The Cochrane Database of Systematic Reviews. - 2002. - Issue 3. Art. No.: CD001258. DOI: 10.1002/14651858.CD001258.
125.Levy R.H., Ragueneau-Majlessi I., Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers // Epilepsy research. - 2001 Aug. - Vol. 46. - Issue 2. - P. 93-99. Accession Number PUBMED 11463510.
126.Lima M.S., Moncrieff J., Soares B.G. Drugs versus placebo for dysthy-mia // Cochrane Database of Systematic Reviews. - 2005. - Issue 2. Art. No.: CD001130. DOI: 10.1002/14651858.CD001130.
127.Lima Reisser A., Lima M.S., Soares B.G., Farrell M. Carbamazepine for cocaine dependence // The Cochrane Database of Systematic Reviews. - 2002. - Issue 2. Art. No.: CD002023. DOI: 10.1002/14651858.CD002023.
128.Londborg P.D., Smith W.T., Glaudin V., Painter J.R. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression // Journal of affective disorders. - 2000 Dec. - Vol. 61. - Issue 1-2. - P. 73-79. Accession Number PUBMED 11099743.
129.Macritchie K.A., Geddes J.R., Scott J. et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder // The Cochrane Database of Systematic Reviews. - 2001. - Issue 3. - Art. No.: CD003196. DOI: 10.1002/14651858.CD003196.
130.Magarey J. The effectiveness of propofol versus midazolam for the sedation of adult ventilated patients in intensive care units (ICUs). - 2000. - P. 1-51. Adelaide, S. Australia, Australia: Joanna Briggs Institute for Evidence Based Nursing and Midwifery.
131.Maguire GA Повышение уровня пролактина при терапии антипсихотиками: механизмы действия и клинические последствия (реферат) = J Clin Psychiatry 2002; 63 (suppl. 4): 56–62 // Психиатрия и психофармакология. - 2006. - Т. 08, № 6.
132.Mann SC, Caroff SN, Keck PE, Lazarus A. Neuroleptic Malignant Syndrome and Related Conditions. 2th ed. Washington, DC: American Psychiatric Publishing, 2003.
133.Margetić B, Aukst-Margetić B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 2010;
19 (5): 429–35.
134.Maria Carolina Hardoy, Alessandra Garofalo, Gisa Mellino, Francesco Tuligi, Mariangela Cadeddu and Mauro Giovanni Carta (2007). «Quetiapine as add-on treatment for bipolar I disorder: efficacy in preventing relapse of depressive episodes». Clinical Practice and Epidemiology in Mental Health 3: 17. DOI:10.1186/1745-0179-3-17.PDF
135.Marques L.O., Lima M.S., Soares B.G. Trifluoperazine for schizophre-nia // Cochrane Database of Systematic Reviews. - 2004. - Issue 1. Art. No.: CD003545. DOI: 10.1002/14651858.CD003545.
136.Marques L.O., Lima M.S., Soares B.G. Trifluoperazine for schizophrenia // The Cochrane Library. - 2002. - Issue 3.
137.Marshall J., Rodarte A., Blumer J., Khoo K.C., Akbari B., Kearns G. Pediatric pharmacodynamics of midazolam oral syrup. Pediatric Pharmacology Research Unit Network // Journal of Clinical Pharmacology. - 2000 Jun. - Vol. 40. - N 6. - P. 578-589.
138.Marson A.G., Williamson P.R., Hutton J.L. et al. Carbamazepine versus valproate monotherapy for epilepsy // The Cochrane Database of Systematic Reviews. - 2000. - Issue 3. Art. No.: CD001030. DOI: 10.1002/14651858.CD001030.
139.Matar H.E., AlMerie M.Q. Oral fluphenazine versus placebo for schizophrenia // Cochrane Database of Systematic Reviews. - 2007. - Issue 1. Art. No.: CD006352. DOI: 10.1002/14651858.CD006352.
140.Matharu L., Ashley P.F. Sedation of anxious children undergoing dental treatment // The Cochrane Database of Systematic Reviews. - 2006. - Issue 1. - Art. No.: CD003877. DOI: 10.1002/14651858.CD003877.pub3.
141.Mattson R.H., Cramer J.A., CollinsJ.F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults // N. Engl. J. Med. - 1992 Sep. - Vol. 327. - Issue 11. - P. 765-771. - Accession Number PUBMED 1298221.
142.Mecarelli O., Vicenzini E., Pulitano P. et al. Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers // The Annals of pharmacotherapy. - 2004 Nov. - Vol. 38. - Issue 11. - P. 1816-1822. Accession Number PUBMED 15367726.
143.Medication-induced movement disorders: Neuroleptic malignant syndrome. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000; 795–8.
144.Meremikwu M., Marson A.G. Routine anticonvulsants for treating cerebral malaria // The Cochrane Database of Systematic Reviews. - 2002. - Issue 2. Art. No.: CD002152. DOI: 10.1002/14651858.CD002152.
145.Mihara K, Kondo T, Suzuki A et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet 2003; 117 (1): 57–60.
146.Miner J.R., Fish S.J., Smith S.W., Biros M.H. Droperidol vs. prochlorperazine for benign headaches in the emergency department // Academic Emergency Medicine. - 2001 Sep. - Vol. 8. - Issue 9. - P. 873-879.
147.Miyasaka L.S., Atallah A.N., Soares B.G.O. Valerian for anxiety disorders // The Cochrane Database of Systematic Reviews. - 2006. - Issue 4. - Art. No.: CD004515. DOI: 10.1002/14651858.CD004515.pub2.
148.Mizuno Y, Takubo H, Mizuta E et al. Malignant Syndrome in Parkinson’s disease: concept and review of the literature.
Parkinsonism Relat Disord 2003; 9 (suppl. 1): S3–9.
149.Mota Neto J.I., Lima M.S., Soares B.G. Amisulpride for schizophrenia // The Cochrane Library. - 2002. - Issue 3.
150.Muller M., Marson A.G., Williamson P.R. Oxcarbazepine versus phenytoin monotherapy for epilepsy // Cochrane Database of Systematic Reviews. - 2006. - Issue 2. Art. No.: CD003615. DOI: 10.1002/14651858.CD003615.
137
151.Naguib M., Samarkandi A.H. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study // Anesthesia & Analgesia. - 2000 Aug. - Vol. 91. - N 2. - P. 473-479.
152.Newcomer JW Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review // CNS Drugs. - 2005. - Т. 19 Suppl 1. - С. 1-93. - PMID 15998156.
153.Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care 2009; 10 (1): 136–40.
154.Nicholson D, Chiu W. Neuroleptic malignant syndrome. Geriatrics 2004; 59 (8): 36, 38–40.
155.Novo I.P., Lima M.S. Benzodiazepines for panic // Cochrane Database of Systematic Reviews. - 2004. - Issue 1. Art. No.: CD004693. DOI: 10.1002/14651858.CD004693.
156.Ntais C., Pakos E., Kyzas P., Ioannidis J.P.A. Benzodiazepines for alcohol withdrawal // The Cochrane Database of Systematic Reviews. - 2005. - Issue 3. - Art. No.: CD005063. DOI: 10.1002/14651858.CD005063.pub2.
157.Ogutu B.R., Newton C.R., Muchohi S.N. et al. Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration // British Journal of Clinical Pharmacology. - 2002 Dec. - Vol. 54. - Issue 6. - P. 635-642. Accession Number PUBMED 12492612.
158.Okoromah C.A.N., Lesi F.E.A. Diazepam for treating tetanus // TheCochrane Database of Systematic Reviews. - 2004. - Issue 1. - Art. No.: CD003954. DOI: 10.1002/14651858.CD003954.pub2.
159.Ong KC, Chew EL, Ong YY. Neuroleptic malignant syndrome without neuroleptics. Singapore Med J 2001; 16 (5): 960–2.
160.Onofrj M., Paci C., D'Andreamatteo G., Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week doubleblind cross-over study vs. low-dose pimozide // Journal of Neurology. - 2000. - Jun. - Vol. 247. - Issue 6. - P. 443-446.
161.Oomura M, Terai T, Sueyoshi K. Reversible cardiomyopathy as the autonomic involvement of neuroleptic malignant syndrome. Intern Med 2004; 43 (12): 1162–5.
162.Osborn D.A., Jeffery H.E., Cole M. Opiate treatment for opiate withdrawal in newborn infants // The Cochrane Database of Systematic Reviews. - 2005. - Issue 3. - Art. No.: CD002059. DOI: 10.1002/14651858.CD002059.pub2.
163.Osborn D.A., Jeffery H.E., Cole M.J. Sedatives for opiate withdrawal in newborn infants // The Cochrane Database of Systematic Reviews. - 2005. - Issue 3. - Art. No.: CD002053. DOI: 10.1002/14651858.CD002053.pub2.
164.Paparrigopoulos T, Tzavellas E, Ferentinos P et al. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry 2009; 10 (1): 70–3.
165.Patel U, Agrawal M, Krishnan P, Niranjan S. Neuroleptic malignant syndrome presenting as pulmonary edema and severe bronchorrhea. J Nat Med Assoc 2002; 94 (4): 279–82.
166.Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review // CNS Drugs. - 2014 May. - Vol. 28, no. 5. - P. 421-53. - DOI:10.1007/s40263-014-0157-3. - PMID 24677189.
167.Picard LS, Lindsay S, Strawn JR et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008; 28 (4): 530–5.
168.Prasad K., Al-Roomi K., Krishnan P.R., Sequeira R. Anticonvulsant therapy for status epilepticus // The Cochrane Database of Systematic Reviews. - 2005. - Issue 4. - Art. No.: CD003723. DOI: 10.1002/14651858.CD003723.pub2.
169.Purse M. Neuroleptic malignant syndrome (NMS). Med Rev Board 2006: – bipolar.about.com/od/sideeffectslibrary/g
170.Pwee K.H., Shukla V.K., Herrmann N., Skidmore B. Novel antipsychotics for agitation in dementia: a systematic review. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). - 2003. - 57. - Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
171.Pylvanen V., Knip M., Pakarinen A.J. et al. Fasting serum insulin and lipid levels in men with epilepsy // Neurology. - 2003.
-Feb. - Vol. 60. - Issue 4. - P. 571-574. - Accession Number PUBMED 12601094.
172.Quraishi S., David A., Adams C.E. Depot bromperidol decanoate for schizophrenia // The Cochrane Library. - 2002. - Issue
3.
173.Ragueneau-Majlessi I., Levy R.H., Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women // Epilepsia. - 2002 Jul. - Vol. 43. - Issue 7. - P. 697-702. Accession Number PUBMED 12102671.
174.Ragueneau-Majlessi I., Levy R.H., Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin // Epilepsy research. - 2001 Nov. - Vol. 47. - Issue 1-2. - P. 55-63. Accession Number PUBMED 11673021.
175.Rajagopal S. Catatonia. Advanc Psychiatr Treatm 2007; 13: 51–9.
176.Rendell J.M., Geddes J.R. Risperidone in long-term treatment for bipolar disorder // Cochrane Database of Systematic Reviews. - 2006. - Issue 4.
177.Rendell J.M., Gijsman H.J., Bauer M.S. et al. Risperidone alone or in combination for acute mania // Cochrane Database of Systematic Reviews. - 2006. - Issue 1.
178.Rendell J.M., Gijsman H.J., Keck P. et al. Olanzapine alone or in combination for acute mania // Cochrane Database of Systematic Reviews. - 2003. - Issue 1.
179.Ristikankare M., Julkunen R., Mattila M., Laitinen T., Wang S.X., Heikkinen M., Janatuinen E., Hartikainen J. Conscious sedation and cardiorespiratory safety during colonoscopy // Gastrointestinal Endoscopy. - 2000 Jul. - Vol. 52. - N 1. - P. 48-54.
180.Rodriguez OP, Dowell MS. Acasereport of neuroleptic malignant syndrome without fever in a patient given aripiprazole. J Okla State Med Assoc 2006; 99 (7): 435–8.
181.Romic P. Total intravenous anesthesia with propofol with midazolam coinduction - the anesthesia of choice in cataract surgery // Vojnosanitetski Pregled. - 2000 Mar-Apr. - Vol. 57. - N 2. - P. 175-186.
182.Roth B.L., Sheffler D.J., Potkin S.G. Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?
Clinical Neuroscience Research. 2003; 3: 108117.
183.Ruddy, House A. Psychosocial interventions for conversion disorder // The Cochrane Database of Systematic Reviews. - 2005. - Issue 4. - Art. No.: CD005331. DOI: 10.1002/14651858.CD005331.pub2.
184.Saarto T., Wiffen P.J. Antidepressants for neuropathic pain // The Cochrane Database of Systematic Reviews. - 2007. - Issue 4. - Art. No.: CD005454. DOI: 10.1002/14651858.CD005454.pub2.
185.Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res 2005; 135 (3): 249–56.
186.Sachs G.S., Bowden C.L., Chou J.C. et al. Risperidone versus placebo as combination therapy to mood stabilizers in the treatment of the manic phase of bipolar disorder: focus on efficacy // 52nd Institute on Psychiatric Services. - 2000 Oct.
187.Saletu B., Saletu-Zyhlarz G., Anderer P., Brandstatter N., Frey R., Gruber G., Klosch G., Mandl M., Grunberger J., Linzmayer L. Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium (R)) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods // Neuropsychobiology. - 1997. - Vol. 36. - Issue 3. - P. 130-152. Accession Number EMBASE 1997276366.
188.Sallas W.M., Milosavljev S., D'souza J., Hossain M. Pharmacokinetic drug interactions in children taking oxcarbazepine // Clinical pharmacology and therapeutics. - 2003. - Aug. - Vol. 74. - Issue 2. - P. 138-149. - Accession Number PUBMED 12891224.
189.Salters-Pedneault K. Neuroleptic Malignant Syndrome – A Definition of Neuroleptic Malignant Syndrome. Med Rev Board 2009. bipolar.about.com/od/sideeffectslibrary/g
138
190.Sanmaneechai O, Likasitwattanakul S. Neuroleptic malignant syndrome: a report of 2 cases. Chiang Mai Med Bull 2005; 44
(2): 73–8.
191.Schierhout G., Roberts I. Anti-epileptic drugs for preventing seizures following acute traumatic brain injury // The Cochrane Database of Systematic Reviews. - 2001. - Issue 4. Art. No.: CD000173. DOI: 10.1002/14651858.CD000173.
192.Serrano-Duenas M. Neuroleptic malignant syndrome-like, or – dopaminergic malignant syndrome – due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord 2003; 9 (3): 175–8.
193.Shakespeare D.T., Boggild M., Young C. Anti-spasticity agents for multiple sclerosis // The Cochrane Database of Systematic Reviews. - 2003. - Issue 4. - Art. No.: CD001332. DOI: 10.1002/14651858.CD001332.
194.Shank R.P., Doose D.R., Streeter A.J., Bialer M. Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase // Epilepsy Research. - 2005 Feb. - Vol. 63. - Issue 2-3. - P. 103-112. Accession Number PUBMED 15715969.
195.Shitij Kapur, MD, PhD, FRCPC; Robert Zipursky, MD, FRCPC; Corey Jones, BSc; C. S. Shammi, MD, FRCPC; Gary
Remington, MD, PhD, FRCPC; Philip Seeman, MD, PhD (June 2000). «A Positron Emission Tomography Study of Quetiapine in Schizophrenia». Arch Gen Psychiatry 57 (6).
196.Sierra-Biddle D, Herran A, Diez-Aja S et al. Neuroleptic malignant syndrome and olanzapine [letter]. J Clin Psychopharmacol 2000; 20 (6): 704–5.
197.Skidmore-Roth Linda. Mosby's Handbook of Herbs & Natural Supplements, 2nd Edition RN, MSN, NP, Softcover, 2004.
198.Soares B.G., Fenton M., Chue P. Sulpiride for schizophrenia // The Cochrane Library. - Issue 3. - 2002.
199.Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013). «Adjunctive Atypical Antipsychotic
Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes». PLoS Med 10 (3). DOI:10.1371/journal.pmed.1001403. PMID 23554581.
200.Srisurapanont M., Maneeton B., Maneeton N. Quetiapine for schizophre-nia // The Cochrane Library. - Issue 2. - 2004.
201. Stahl S.M. Новые достижение в терапии шизофрении. В кн.: Шизофрения. Изучение спектра психозов
(ред. Ancill R.J., Holliday S., Higenbottam J.). М: Медицина. 2001: 154-170.
202.Stanfield SC, Privette T. Neuroleptic malignant syndrome associated with olanzapinetherapy: a case report. J Emerg Med
2000; 19 (4): 355–7.
203.Stanford M.S., Houston R.J., Mathias C.W. et al. A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression // Psychiatry Research. - 2001 Sep. - Vol. 103. - Issue 2-3. - P. 193-203. Accession Number PUBMED 11549407.
204.SteinD.J., Ipser J.C., van Balkom A.J. Pharmacotherapy for social anxiety disorder // Cochrane Database of Systematic Reviews. - 2000. - Issue 4. Art. No.: CD001206. DOI: 10.1002/14651858.CD001206.
205.Steinhoff B.J., Trinka E., Wieser H.G. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland // Seizure : the journal of the British Epilepsy Association. - 2005 Oct. - Vol. 14. - Issue 7. - P. 490-496. Accession Number PUBMED 16169256.
206.Stotz M, Thummler D, Schurch M et al. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiparkinsonian medication. Br J Anaesth 2004; 93 (6): 868–71.
207.Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164 (6): 870–6.
208.Stubner S, Rustenbeck E, Grohmann R et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004; 37 (suppl. 1): S54–64.
209.Sultana A., Reilly J., Fenton M. Thioridazine for schizophrenia // The Cochrane Library. - 2002. - Issue 3.
210.Susman VL. Clinical Management of Neuroleptic Malignant Syndrome. Psychiatric Quarterly 2001; 72: 325–36.
211.Sweetman S. (Ed), Martindale: The complete drug reference. London: Pharmaceutical Press. Electronic version, (Edition
[2005]).
212.Szarfman A, Tonning JM, Levine JG, Doraiswamy PM (June 2006). «Atypical antipsychotics and pituitary tumors: a
pharmacovigilance |
study». Pharmacotherapy26 (6): |
748–58. DOI:10.1592/phco.26.6.748. PMID |
16716128. Перевод: Атипичные |
антипсихотики и опухоли гипофиза: исследование фармакобдительности |
|
||
213.Takubo H, Harada T, Hashimoto T et al. A collaborative study on the malignant syndrome in Parkinson’s disease and related disorders. Parkinsonism Relat Disord 2003; 9 (suppl. 1): S31–41.
214.Taricco M., Adone R., Pagliacci C., Telaro E. Pharmacological interventions for spasticity following spinal cord injury // The Cochrane Database of Systematic Reviews. - 2000. - Issue 2. - Art. No.: CD001131. DOI: 10.1002/14651858.CD001131.
215.Taylor S., Tudur Smith C., Williamson P.R., Marson A.G. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures // The Cochrane Database of Systematic Reviews. - 2003. - Issue 2. Art. No.: CD002217. DOI: 10.1002/14651858.CD002217.
216.Temkin N.R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials // Epilepsia. - 2001. - Vol. 42(4). - P. 515-524.
217.This record should be cited as: K. Vasudev, K. Macritchie, J.R. Geddes, S. Watson, A.H. Young. Topiramate for acute affective episodes in bipolar disorder // Cochrane Database of Systematic Reviews. - 2006. - Issue 1. Art. No.: CD003384. DOI: 10.1002/14651858.CD003384.pub2.
218.Thornley B., Rathbone J., Adams C.E. et al. Chlorpromazine versus placebo for schizophrenia. Cochrane Systematic Review.
2004, Issue 2.
219.Tomson T., Dahl M.L., Kimland E. Therapeutic monitoring of antiepileptic drugs for epilepsy // Cochrane Database of Systematic Reviews. - 2007. - Issue 1. Art. No.: CD002216. DOI: 10.1002/14651858.CD002216.
220.Tonkonogy J, Sholevar DP. Neuroleptic Malignant Syndrome. eMedicine 2010. medscape.com/article/288482-overview
221.Trip J., Drost G., van Engelen B.G.M., Faber C.G. Drug treatment for myotonia // The Cochrane Database of Systematic Reviews. - 2006. - Issue 1. - Art. No.: CD004762. DOI: 10.1002/14651858.CD004762.pub2.
222.Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs
2009; 23 (6): 477–92.
223.Tsai HC, Kuo PH, Yang PC. Fever, consciousness disturbance, and muscle rigidity in a 68-year-old man with depressive disorder. Chest 2003; 124 (4): 1598–601.
224.Tudur Smith C., Marson A.G., Clough H.E., Williamson P.R. Carbamazepine versus phenytoin monotherapy for epilepsy // The Cochrane Database of Systematic Reviews. - 2002. - Issue 2. Art. No.: CD001911. DOI: 10.1002/14651858.CD001911.
225.Tudur Smith C., Marson A.G., Williamson P. R. Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures // The Cochrane Database of Systematic Reviews. - 2001. - Issue 4. - Art. No.: CD001769. DOI: 10.1002/14651858.CD001769.
226.Tudur Smith C., Marson A.G., Williamson P.R. Carbamazepine versus phenobarbitone monotherapy for epilepsy // The Cochrane Database of Systematic Reviews. - 2003. - Issue 1. Art. No.: CD001904. DOI: 10.1002/14651858.CD001904.
227.Tudur Smith C., Marson A.G., Williamson P.R. Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures // The Cochrane Database of Systematic Reviews. - 2001. - Issue 4. Art. No.: CD001769. DOI: 10.1002/14651858.CD001769.
139
228.Tulloch K.J., Zed P.J. Intramuscular olanzapine in the management of acute agitation // Annals of Pharmacotherapy. - 2004.
-38(12):2128-2135.
229.Tural U, Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci 2010; 64 (1): 79–87.
230.Ucar M., Neuvonen M., Luurila H. et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid // European journal of clinical pharmacology. - 2004 Feb. - Vol. 59. - Issue 12. - P. 879-882. Accession Number PUBMED 14691614.
231.Valenca A.M., Nardi A.E., Mezzasalma M.A. et al. Therapeutic response to benzodiazepine in panic disorder subtypes // São
Paulo medical journal. - 2003 Mar. - Vol. 121. - Issue 2. - P. 77-80. Accession Number PUBMED 12870055.
232.Valenca A.M., Nardi A.E., Nascimento I. et al. Double-blind clonazepam vs placebo in panic disorder treatment // Arquivos de neuro-psiquiatria. - 2000 Dec. - Vol. 58. - Issue 4. - P. 1025-1029. Accession Number PUBMED 11105068.
233.Vasudev K., Goswami U., Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder // Psychopharmacology. - 2000 May. - Vol. 150. - Issue 1. - P. 15-23. - Accession Number PUBMED 10867972.
234.Vasudev K., Macritchie K., Geddes J.R. et al. Topiramate for acute affective episodes in bipolar disorder // Cochrane Database of Systematic Reviews. - 2006. - Issue 1. Art. No.: CD003384. DOI: 10.1002/14651858.CD003384.
235.Vedantam S A Silenced Drug Study Creates An Uproar // The Washington Post. - March 18, 2009.
236.Viejo LF, Morales V, Puñal P et al. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand 2003; 107 (1): 45–9.
237.Voderholzer U., Backhaus J., Hornyak M., Feige B., Riemann D., Hohagen F., Berger M. Effects of acute withdrawal from newer hypnotics with short half-life on sleep eeg: a placebocontrolled trial in healthy subjects // XXIst Collegium Internationale Neuropsychopharmacologicum, Glasgow, Scotland. - 12th-16th July. - 1998.
238.Volz A., Khorsand V., Gillies D., Leucht S. Benzodiazepines for schizophrenia // Cochrane Database of Systematic Reviews.
-2007. - Issue 1. Art. No.: CD006391. DOI: 10.1002/14651858.CD006391.
239.Voros V, Osvath P, Fekete S, Tenyi T. Antipsychotics and rhabdomyolysis. Differential diagnosis and clinical significance of elevated serum creatine kinase levels in psychiatric practice. Psychiatr Hung 2009; 24 (3): 175–84.
240.Waldorf S. Update for nurse antsthetists, Neuroleptic Malignant Syndrome. AANA J 2003; 71: 389–94.
241.Walker K.J., Smith A.F., Pittaway A.J. Premedication for anxiety in adult day surgery // The Cochrane Database of Systematic Reviews. - 2003. - Issue 1. - Art. No.: CD002192. DOI: 10.1002/14651858.CD002192.
242.Waraich P. S., Adams C.E., Roque M. et al. Haloperidol dose for the acute phase of schizophrenia // Cochrane Database of Systematic Reviews. - 2002. - Issue 2.
243.Ward C. Neuroleptic malignant syndrome in a patient with Parkinson’s disease: a case study. J Neurosci Nurs 2005; 37 (3):
160–2.
244.Weisler R.H., Keck P.E., Swann A.C. et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial // The Journal of clinical psychiatry. - 2005 Mar. - Vol. 66. - Issue 3. - P. 323-330. Accession Number PUBMED 15766298.
245.Wiffen P., Collins S., McQuay H. et al. Anticonvulsant drugs for acute and chronic pain // Cochrane Database of Systematic Reviews. - 2005. - Issue 3. Art. No.: CD001133. DOI: 10.1002/14651858.CD001133.
246.Wiffen P., Collins S., McQuay H. et al. Anticonvulsant drugs for acute and chronic pain // The Cochrane Library. - Issue 3. -
2002.
247.Wiffen P.J., McQuay H.J., Moore R.A. Carbamazepine for acute and chronic pain // The Cochrane Database of Systematic Reviews. - 2005. - Issue 3. Art. No.: CD005451. DOI: 10.1002/14651858.CD005451.
248.Wilding J., Van Gaal L., Rissanen A. et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects // Int. J. Obes. Relat. Metab. Disord. - 2004 Nov. - Vol. 28 (11). - P. 1399-410.Click here to read. Accession Number PUBMED 15486569.
249.Wille R.T., Barnett J.L., Chey W.D. et al. Routine droperidol pre-medication improves sedation for ERCP // Gastrointestinal Endoscopy. - 2000 Sep. - Vol. 52. - P. 362-366.
250.Yacoub A, Kohen I, Caraballo A, Francis A. Rating Scale Neuroleptic Malignant Syndrome. Biol Psychiatry 2004; 55: 89S.
251.Yamamura Yuichi, Kokubu Tatsuro, Ueda Einosuke, Yano Saburo, Morimoto Yasuhiko, Konishiike Joichi, Yamamoto Minoru, Yoshida Shigeru, Kashiwamura Shigeru, Kotani Akira Clinical Effects of Lorazepam on Insomnia in the Field of Internal MedicineEvaluated by Double Blind Study Using Nitrazepam and Placebo as Control Drugs // Rinsho Hyoka (Clinical Evaluation). - 1978. - Vol. 6. - Issue 2. - P. 201-221.
252.Yatham L.N. Efficacy and tolerability of risperidone as combination therapy in bipolar mania: results from a randomised, double-blind study // Journal of the European College of Neuropsychopharmacology. - 2000. - Vol. 10. - N 3. - P. 250.
253.Yi M.S., Li W.H. Venlafaxine vs sulpiride in adjuvant treatment of negative symptoms of schizophrenia // Chinese Journal of New Drugs and Clinical Remedies. - 2000. - Vol. 19. - N 5. - P. 377-380.
254.Александровский Ю.А. Краткий психиатрический словарь. М.: РЛС-2009, 2008. - 128 c.
255.Бажин А. А. Справочник по психофармакологии. - СПб.: СпецЛит, 2009. - С. 18. - 64 с. - ISBN 978-5-299-00399-4.
256.Бурбелло А.Т., Бабак С.В., Андреев Б.В., Колбин А.С., Горячкина К.А.Неблагоприятные побочные реакции лекарственных средств (пособие для врачей) / Под ред. А.Т.Бурбелло. - Санкт-Петербург, 2008.
257.Бурчинский С. Г. Биполярные аффективные расстройства: возможности атипичных нейролептиков и критерии выбора // Нейро News: психоневрология и нейропсихиатрия. - Ноябрь 2010. - № 6 (25).
258.Бурчинский С.Г. Проблема безопасности в стратегии фармакотерапии атипичными нейролептиками // Нейро News: психоневрология и нейропсихиатрия. - Сентябрь 2010. - № 5 (24).
259.Волков ВП. Кожные осложнения фенотиазиновой терапии (обзор литературы). Психиатрия и психофармакотерапия
2010; 12 (3): 33–7.
260.Г.А. Мельниченко, Е.И. Марова, Л.К. Дзеранова, В.В. Вакс.Гиперпролактинемия у женщин и мужчин: Пособие для врачей. - Москва: ГУ «Эндокринологический научный центр РАМН». Институт клинической эндокринологии, 2007. - 33 с.
261.Гётше П. Смертельно опасные лекарства и организованная преступность: Как большая фарма коррумпировала здравоохранение / [Пер. с англ. Л. Е. Зиганшиной]. - Москва: Издательство «Э», 2016. - 464 с. - (Доказательная медицина). - 3000
экз. - ISBN 978-5-699-83580-5.
262. Горобец Л.Н. Эндокринные побочные эффекты нейролептической терапии. Проверено 6 ноября 2011. Архивировано из первоисточника 22 февраля 2012.
263.Горобец Л.Н., Поляковская Т.П., Литвинов А.В. и др. Проблема остеопороза у больных с психическими расстройствами. Часть 1 // Социальная и клиническая психиатрия. - 2012. - Т. 22, № 3. - С. 107-112.
264.Горобец Л.Н., Поляковская Т.П., Литвинов А.В. и др. Проблема остеопороза у больных с психическими расстройствами. Часть 2 // Социальная и клиническая психиатрия. - 2013. - Т. 23, № 1. - С. 87-92.
140